Earnings News - Candlesense

G. WILLI-FOOD INTERNATIONAL REPORTS THE RESULTS OF SECOND QUARTER 2025 WITH RECORD HIGH RESULTS

THE COMPANY REPORT ITS HIGHEST-EVER QUARTERLY REVENUE, OPERATING PROFIT, PROFIT BEFORE TAX, AND NET INCOME YAVNE, Israel, Aug. 12, 2025 /PRNewswire/ -- G. Willi-Food International Ltd. (NASDAQ: WIL...

What technical chart patterns are emerging for WILC after the earnings announcement? How could macro‑economic factors (e.g., inflation, commodity prices) influence the durability of these results? Does the earnings beat suggest a potential shift in market share within the industry?

Symbol: WILC

27 days ago

Read more prnewswire

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

NEW HOPE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...

Are there any changes in the senior management or board that could affect strategic direction? What is the market’s reaction to this release (e.g., price movement, volume) and how does it compare to analyst expectations? Did the company provide any updates on the status of its key clinical programs and their timelines?

Symbol: OBIO

27 days ago

IQST - IQSTEL Blew Past Its Goals With $35 Million in July Revenue -- Surpasses $400 Million Annual Run Rate Five Months Ahead of Schedule on Path to $1 Billion by 2027

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- IQSTEL Inc. (NASDAQ: IQST) today announced preliminary July 2025 revenue of approximately $35 million, surpassing the Company's $400 million annualized reven...

What forward‑looking statements regarding the $1 billion revenue target by 2027 could affect the long‑term outlook and positioning? What short‑term market reaction (price movement, trading volume) is anticipated from investors and traders? What impact will this performance have on the company’s debt levels and leverage ratios?

Symbol: IQST

27 days ago

Read more prnewswire

Guerrilla RF Reports Second Quarter 2025 Results

GREENSBORO, N.C.--(BUSINESS WIRE)---- $GUER--Guerrilla RF Reports Second Quarter 2025 Results.

What is the market's current sentiment toward Guerrilla RF, and how might this earnings release shift that sentiment? Are there any upcoming catalysts, such as product launches or regulatory approvals, that could move the stock in the near term? How might the reported results impact the company's debt levels or liquidity position?

Symbol: GUER

27 days ago

Eagle Point Income Company Inc. Announces Second Quarter 2025 Financial Results and Declares Fourth Quarter 2025 Common and Preferred Distributions

GREENWICH, Conn.--(BUSINESS WIRE)---- $EIC--Eagle Point Income Company Inc. (the “Company”) (NYSE: EIC, EICA, EICB, EICC) today announced financial results for the quarter ended June 30, 2025 and c...

Are there any tax or regulatory considerations related to the preferred stock distributions that could affect investor returns? Will the Q2 results trigger any changes in analyst sentiment or target price adjustments for the stock? What macro‑economic or market conditions could influence the company's cash flow and distribution sustainability moving forward?

Symbol: EIC

27 days ago

Eagle Point Credit Company Inc. Announces Second Quarter 2025 Financial Results and Declares Fourth Quarter 2025 Common and Preferred Distributions

GREENWICH, Conn.--(BUSINESS WIRE)---- $ECC--Eagle Point Credit Company Inc. (the “Company”) (NYSE: ECC, ECCC, ECC PRD, ECCF, ECCU, ECCV, ECCW, ECCX) today announced financial results for the quarte...

What is the market's reaction to this release likely to be in terms of short‑term price volatility? How might the CLO equity acquisitions influence the company's net asset value (NAV) and price-to-earnings (P/E) multiples? Are there any tax considerations for investors related to the preferred stock distributions announced?

Symbol: ECC

27 days ago

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

HOUSTON, Aug. 12, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulato...

What is the expected impact of this earnings release on analyst sentiment and upcoming research coverage? How might the sentiment rating of 10 (extremely positive) influence market perception and short‑term trading activity? Did the company address any risk factors or operational challenges that might impact future earnings?

Symbol: COYA

27 days ago

Read more prnewswire

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor...

What is the expected impact on APRE’s stock price volatility and short‑term trading opportunities? How will the Q2 earnings and clinical update affect analyst coverage and target‑price revisions? What are the key downside risks (e.g., failure to meet endpoints, safety concerns) that could impact the stock price?

Symbol: APRE

27 days ago

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovativ...

How might macro‑economic factors (e.g., interest rates, biotech funding environment) impact Monopar's ability to raise additional capital if needed? What is the market's perception of the recent developments—are analysts upgrading/downgrading the stock, and what are the new target price revisions? Did the company disclose any changes in its capital structure, such as new debt facilities, equity offerings, or share buyback programs?

Symbol: MNPR

27 days ago

IM Cannabis Reports Second Quarter 2025 Financial Results

IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" ...

Does the company plan any share buybacks or dividend adjustments based on this quarter’s performance? What are the key risks highlighted in the MD&A that could impact future performance? What is the analyst consensus rating and target price, and how might this earnings release affect it?

Symbol: IMCC

27 days ago

Read more prnewswire